Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05992675 · ClinicalTrials.gov registry record
Air Optix® Night and Day® Aqua Continuous Wear
A clinical trial, sponsored by Alcon Research.
- Completed
- Registry status
- 1,256
- Enrollment target
NCT05992675: Completed study, sponsored by Alcon Research.
NCT05992675 is a clinical trial that has completed, run by Alcon Research. The registered enrollment target is 1,256 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05992675 has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- 1,256 participants
- Enrollment target
Study Summary
The purpose of this retrospective, Post-Market Clinical Follow-Up (PMCF) study is to assess the long term performance and safety of Air Optix® Night and Day® Aqua (AONDA) contact lenses in a real-world setting when worn as 30 days of continuous wear for vision correction.
Primary Outcome
The subject's chart will be reviewed for distance visual acuity.
Interventions
- DEVICE Balafilcon A contact lenses
- DEVICE Lotrafilcon A contact lenses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,256 participants |
| Start Date | 2023-10-05 |
| Est. Completion | 2024-08-22 |
What the finished NCT05992675 record still lists
NCT05992675 is an observational study that tracks outcomes without assigning an intervention. Its 1,256 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Balafilcon A contact lenses is the first listed.
NCT05992675 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05992675 about?
NCT05992675 is a clinical study titled "Air Optix® Night and Day® Aqua Continuous Wear". The purpose of this retrospective, Post-Market Clinical Follow-Up (PMCF) study is to assess the long term performance and safety of Air Optix® Night and Day® Aqua (AONDA) contact lenses in a real-world setting when worn as 30 days of continuous wear for vision correction.
What is the current status of trial NCT05992675?
This trial is currently completed. The enrollment target is 1,256 participants. The study started on 2023-10-05. Estimated completion is 2024-08-22.
What interventions are being tested in trial NCT05992675?
The interventions under investigation include: Balafilcon A contact lenses (DEVICE), Lotrafilcon A contact lenses (DEVICE).
Who is sponsoring clinical trial NCT05992675?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI